Theradiag Announces the Launch of HUMABDIAG, a Large-scale Research Project Targeting the Bioproduction of Monoclonal Antibodies in Tours - Seite 2

Theradiag CEO Bertrand de Castelnau commented: “The launch of this large-scale project called Humabdiag demonstrates Theradiag’s innovation dynamic. This project in Tours is a strategic one, as it will enable us, via the manufacturing of human monoclonal antibodies, to make progress in and further develop our biotherapy monitoring activity. The value of our partners enhances our expectations for this project, in which Theradiag will be the Business Leader. This unique research project will result in the creation of a new activity that totally complements existing activities and in the high-quality and economical sourcing of our materials.”.

REMINDER:

The Extraordinary Shareholders’ Meeting, on the second call, scheduled for June 10, 2021 is one of your company’s key moments. Your participation is very important; it provides you with an opportunity, through your vote, to participate in Theradiag’s corporate project.

Don’t forget to vote on your financial intermediary’s website via the Votaccess platform or by giving power or proxy as soon as possible.

Financial calendar:

- Extraordinary Shareholders’ Meeting on second call, on Thursday June 10, 2021
- H1 2021 revenue, on Monday July 19, 2021
- H1 2021 results, on Monday September 20, 2021

About Theradiag

Theradiag is the market leader in biotherapy monitoring. Capitalizing on its expertise in the diagnostics market, the Company has been developing, manufacturing, and marketing innovative in vitro diagnostic (IVD) tests for over 30 years.

Theradiag pioneered “theranostics” testing (combining therapy with diagnosis), which measures the efficacy of biotherapy in the treatment of chronic inflammatory diseases. Going beyond mere diagnosis, Theranostics aims to help clinicians set up “customized treatment” for each patient. This method favors the individualization of treatment, evaluation of its efficacy and the prevention of drug resistance. In response to this challenge, Theradiag develops and markets the CE-marked TRACKER range, a comprehensive solution of inestimable medical value.

The Company is based in Marne-la-Vallée, near Paris, has operations in over 70 countries and employs over 60 people. In 2020, the Company posted revenue of €10.4 million. The Theradiag share is listed on Euronext Growth Paris (ISIN: FR0004197747) and is eligible for the French PEA-PME personal equity plan.

For more information about Theradiag, please visit our website: www.theradiag.com